Open AccessEfficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta‐analysis of double‐blind, randomized, placebo‐controlled trials with an enrichment design
Author(s) -
Oya Kazuto,
Sakuma Kenji,
Esumi Satoru,
Hashimoto Yasuhiko,
Hatano Masakazu,
Matsuda Yuki,
Matsui Yuki,
Miyake Nobumi,
Nomura Ikuo,
Okuya Makoto,
Iwata Nakao,
Kato Masaki,
Hashimoto Ryota,
Mishima Kazuo,
Watanabe Norio,
Kishi Taro
Publication year - 2019
Publication title -
neuropsychopharmacology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.661
H-Index - 13
ISSN - 2574-173X
DOI - 10.1002/npr2.12056
Subject(s) - lamotrigine , discontinuation , placebo , lithium (medication) , bipolar disorder , medicine , randomized controlled trial , mood stabilizer , number needed to treat , clinical endpoint , relative risk , meta analysis , bipolar i disorder , mood , psychiatry , confidence interval , mania , epilepsy , alternative medicine , pathology
Aim Whether patients with adult bipolar disorder ( BD ) who have been clinically stabilized with lithium or lamotrigine should continue this medication is not established fully. This systematic review and meta‐analysis evaluated the efficacy and safety of lithium and lamotrigine for maintenance treatment in clinically stable patients with adult BD . Methods This meta‐analysis included only double‐blind, randomized, placebo‐controlled trials with an enrichment design that selected patients who responded acutely to lithium or lamotrigine. Reports prior to November 15, 2018, were retrieved from the PubMed/Cochrane Library/Embase. The primary outcome was the relapse rate due to any mood episode at the study endpoint. Other outcomes were relapse rates due to a manic/hypomanic/mixed episode or depression at the study endpoint, discontinuation rate, death, and death by suicide. Risk ratios (RRs) (95% confidence intervals) were calculated. When the random‐effects model showed significant differences between groups, the number‐needed‐to‐treat ( NNT ) was estimated. Results The search retrieved two studies regarding lithium (N = 218) and four evaluating lamotrigine (N = 706). Both drugs were superior to placebo for reducing the relapse rate due to any mood episode [lithium: RR = 0.52 (0.41‐0.66), P < 0.00001, I 2 = 0%, NNT = 2.3 (1.6‐4.2); lamotrigine: RR = 0.81 (0.70‐0.93), P = 0.004, I 2 = 0%, NNT = 8.3 (5.0‐25.0)] and all‐cause discontinuation. There were no significant differences in other outcomes between lithium or lamotrigine and the placebo groups. Conclusion Both drugs showed benefit for preventing relapse in clinically stable patients with adult BD . However, the number of studies and patients in this analysis was small.